ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
골수염 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 이러한 예상 성장은 당뇨병 발병률 증가, 만성 질환의 부담 증가, 항생제 내성 확산, 바이오마커 기반 검사 채택 증가, 생물막을 파괴하는 약제에 대한 관심 증가에 의해 촉진될 것입니다. 이 기간 동안의 주요 동향으로는 최신 진단 방법의 채택, 인공 지능(AI) 및 디지털 도구의 사용, 치료 및 수술 방법의 개선, AI 기반 방사선학 도구의 통합, 치료 접근법에 기술의 스마트한 통합 등이 있습니다.
만성 질환의 유병률 증가는 골수염 시장의 성장을 촉진할 것으로 예상됩니다. 만성 질환은 지속적인 치료와 관리가 필요한 장기적인 질병입니다. 이러한 증가는 주로 전 세계 인구의 고령화로 인한 것으로, 고령화는 면역 체계를 약화시키고 지속적인 질병 및 감염에 대한 취약성을 높이기 때문입니다. 이러한 만성 질환은 특히 당뇨병 및 혈관 질환이 있는 사람의 면역 방어와 혈액 순환을 약화시켜 골수염의 위험을 높입니다. 이러한 상태는 감염이 만성화될 수 있는 환경을 조성하여 뼈 감염의 가능성을 높이고 회복 과정을 복잡하게 만듭니다. 예를 들어, 2023년 8월 건강 측정 및 평가 연구소(Institute for Health Metrics and Evaluation)의 조사에 따르면 2023년 30세 이상 인구의 15%가 골관절염을 앓고 있으며, 2050년까지 약 10억 명이 영향을 받을 것으로 추정됩니다. 이처럼 만성 질환의 발생률 증가가 골수염 시장 확대에 기여하고 있습니다.
골수염 시장 주요 기업들은 항생제 내성을 극복하고 환자 치료를 개선하기 위해 사전 혼합 정맥 주사액(IV) 솔루션 등 혁신적인 치료법을 도입하고 있습니다. 사전 혼합 IV 용액은 특정 약물이나 전해질을 함유한 즉시 투여 가능한 멸균 액체로, 임상 환경에서 안전성을 높이고 준비 시간을 단축하기 위해 고안되었습니다. 예를 들어, 2024년 9월, 영국에 본사를 둔 제약 회사인 Hikma Pharmaceuticals Plc는 5% 덱스트로오스를 함유한 클린다마이신 주사제를 출시했습니다. 이 의약품은 급성 혈행성 골수염과 같은 뼈 및 관절 감염을 포함하여, 민감한 혐기성 및 그람 양성균에 의해 발생하는 심각한 감염을 치료합니다. 이 약물은 편리한 정맥 주사 치료 옵션을 제공하며, 특히 페니실린 알레르기가 있거나 페니실린이 적합하지 않은 환자에게 유용합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 골수염 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 골수염 시장 : 성장률 분석
세계의 골수염 시장 실적 : 규모와 성장(2019-2024년)
세계의 골수염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 골수염 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 골수염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
골수성 골수염
표재성 골수염
기타 유형
세계의 골수염 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항생제
항진균제
비스테로이드성 항염증제
기타 약물의 유형
세계의 골수염 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
비경구
세계의 골수염 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
온라인 약국
소매 약국
세계의 골수염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 및 진료소
연구기관
진단 질환
진단센터
세계의 골수염 시장 : 수양 골수염 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
급성 골수성 골수염
만성 골수성 골수염
세계의 골수염 시장 : 표재성 골수염유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
급성 표재성 골수염
만성 표재성 골수염
세계의 골수염 시장 : 기타 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
확산 골수염
경화성 골수염
현지화된 골수염
제7장 지역별, 국가별 분석
세계의 골수염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 골수염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
골수염 시장 : 경쟁 구도
골수염 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Novartis AG
GSK plc
Eli Lilly and Company
Siemens Healthineers
Otsuka Pharmaceutical Co. Ltd
Fresenius Kabi AG
Sumitomo Pharma Company Limited
Hikma Pharmaceuticals PLC
Alkem Laboratories Ltd.
Torrent Pharmaceuticals Ltd.
Wockhardt Hospitals
Basilea Pharmaceutica Ltd.
Paratek Pharmaceuticals Inc.
Debiopharm International SA
Accord Healthcare Limited
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
골수염 시장(2029년) : 새로운 기회를 제공하는 국가
골수염 시장(2029년) : 새로운 기회를 제공하는 부문
골수염 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Osteomyelitis is a bone infection and inflammation that generally arises due to bacteria or fungi spreading through the bloodstream or from adjacent tissues. This condition can lead to bone damage and reduced blood circulation. Common symptoms include bone pain, fever, swelling, and in some cases, drainage of pus.
There are several primary types of osteomyelitis, including medullary osteomyelitis, superficial osteomyelitis, and others. Medullary osteomyelitis occurs when the infection is concentrated in the bone marrow cavity, typically stemming from hematogenous sources, with Staphylococcus aureus being the most frequent cause. Treatment options include a range of drug classes such as antibiotics, antifungals, non-steroidal anti-inflammatory drugs (NSAIDs), and others, which are administered either orally or through parenteral routes. These treatments are made available through hospital pharmacies, online pharmacies, and retail pharmacies, serving end-users such as hospitals and clinics, research institutions, diagnostic laboratories, and diagnostic centers. This organized framework ensures effective treatment delivery and availability for patients affected by osteomyelitis.
The osteomyelitis market research report is one of a series of new reports from The Business Research Company that provides osteomyelitis market statistics, including the osteomyelitis industry's global market size, regional shares, competitors with the osteomyelitis market share, detailed osteomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the osteomyelitis market. This osteomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The osteomyelitis market size has grown strongly in recent years. It will grow from $1.02 billion in 2024 to $1.11 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The market's historical expansion can be attributed to advancements in bone grafting and regenerative medicine, increased healthcare spending, a growing elderly population, enhanced diagnostic capabilities, and a surge in intravenous (IV) drug usage.
The osteomyelitis market size is expected to see strong growth in the next few years. It will grow to $1.56 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. This anticipated growth is driven by a higher occurrence of diabetes, the rising burden of chronic illnesses, the spread of antibiotic resistance, increased adoption of biomarker-based testing, and heightened interest in agents that disrupt biofilms. Key trends during this period include the adoption of cutting-edge diagnostic methods, the use of artificial intelligence (AI) and digital tools, improvements in both treatment and surgical methods, the integration of AI-powered radiology tools, and the smart incorporation of technology into therapeutic approaches.
The increasing prevalence of chronic conditions is anticipated to drive the growth of the osteomyelitis market. Chronic conditions are long-term illnesses that often require ongoing treatment and management. This rise is largely attributed to the aging global population, as aging tends to weaken the immune system and increase vulnerability to persistent illnesses and infections. These chronic conditions elevate the risk of osteomyelitis by compromising immune defenses and blood circulation, especially in individuals with diabetes and vascular diseases. Such conditions foster an environment where infections can become chronic, heightening the chance of bone infection and complicating the recovery process. For example, in August 2023, a survey by the Institute for Health Metrics and Evaluation reported that 15% of people aged 30 and above had osteoarthritis in 2023, with projections estimating nearly 1 billion affected individuals by 2050. As a result, the increasing incidence of chronic conditions is contributing to the expansion of the osteomyelitis market.
Key players in the osteomyelitis market are introducing innovative treatments, such as premixed intravenous (IV) solutions, to address antibiotic resistance and enhance patient care. Premixed IV solutions are ready-to-administer sterile liquids containing specific medications or electrolytes, intended to increase safety and reduce preparation time in clinical settings. For instance, in September 2024, Hikma Pharmaceuticals Plc, a pharmaceutical company based in the UK, introduced a clindamycin injection formulated with 5% dextrose. This drug treats serious infections caused by susceptible anaerobic and gram-positive bacteria, including bone and joint infections such as acute hematogenous osteomyelitis. It offers a convenient IV treatment option, particularly beneficial for patients with penicillin allergies or when penicillin is unsuitable.
In March 2024, BiomX Inc., a biotechnology firm based in Israel, acquired Adaptive Phage Therapeutics Inc. for an undisclosed sum. This acquisition aims to establish BiomX as a leading phage therapy developer with a robust pipeline focused on Phase 2 assets for treating chronic pulmonary infections in cystic fibrosis and diabetic foot osteomyelitis. Adaptive Phage Therapeutics Inc., headquartered in the United States, is engaged in advancing phage therapy solutions specifically for osteomyelitis, including infections associated with diabetic foot ulcers.
Major players in the osteomyelitis market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Otsuka Pharmaceutical Co. Ltd, Fresenius Kabi AG, Sumitomo Pharma Company Limited, Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt Hospitals, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Debiopharm International SA, Accord Healthcare Limited, Melinta Therapeutics LLC, Cempra Inc., MicuRx Pharmaceuticals Inc., and Durata Therapeutics Inc.
North America was the largest region in the osteomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in osteomyelitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the osteomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The osteomyelitis market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical debridement, infection control, antimicrobial therapy, hospitalization, post-operative rehabilitation, and long-term care management. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteomyelitis market also includes sales of antibiotic-loaded bone cement, bone graft materials, orthopedic implants, wound care products, diagnostic kits, and surgical instruments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Osteomyelitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on osteomyelitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for osteomyelitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteomyelitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Medullary Osteomyelitis; Superficial Osteomyelitis; Other Types
2) By Drug Type: Antibiotics; Antifungals; Non-Steroidal Anti-Inflammatory Drugs; Other Drug Types
3) By Route Of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmay; Online Pharmacy; Retail Pharmacy
5) By End-User: Hospital And Clinics; Research Organization; Diagnostic Diseases; Diagnostic Centers
Subsegments:
1) By Medullary Osteomyelitis: Acute Medullary Osteomyelitis; Chronic Medullary Osteomyelitis
2) By Superficial Osteomyelitis: Acute Superficial Osteomyelitis; Chronic Superficial Osteomyelitis
3) By Other Types: Diffuse Osteomyelitis; Sclerosing Osteomyelitis; Localized Osteomyelitis
Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Abbott Laboratories
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Osteomyelitis Market Characteristics
3. Osteomyelitis Market Trends And Strategies
4. Osteomyelitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Osteomyelitis Growth Analysis And Strategic Analysis Framework
5.1. Global Osteomyelitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Osteomyelitis Market Growth Rate Analysis
5.4. Global Osteomyelitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Osteomyelitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Osteomyelitis Total Addressable Market (TAM)
6. Osteomyelitis Market Segmentation
6.1. Global Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Medullary Osteomyelitis
Superficial Osteomyelitis
Other Types
6.2. Global Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antibiotics
Antifungals
Non-Steroidal Anti-Inflammatory Drugs
Other Drug Types
6.3. Global Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Osteomyelitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmay
Online Pharmacy
Retail Pharmacy
6.5. Global Osteomyelitis Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital And Clinics
Research Organization
Diagnostic Diseases
Diagnostic Centers
6.6. Global Osteomyelitis Market, Sub-Segmentation Of Medullary Osteomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Medullary Osteomyelitis
Chronic Medullary Osteomyelitis
6.7. Global Osteomyelitis Market, Sub-Segmentation Of Superficial Osteomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Superficial Osteomyelitis
Chronic Superficial Osteomyelitis
6.8. Global Osteomyelitis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diffuse Osteomyelitis
Sclerosing Osteomyelitis
Localized Osteomyelitis
7. Osteomyelitis Market Regional And Country Analysis
7.1. Global Osteomyelitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Osteomyelitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Osteomyelitis Market
8.1. Asia-Pacific Osteomyelitis Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Osteomyelitis Market
9.1. China Osteomyelitis Market Overview
9.2. China Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Osteomyelitis Market
10.1. India Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Osteomyelitis Market
11.1. Japan Osteomyelitis Market Overview
11.2. Japan Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Osteomyelitis Market
12.1. Australia Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Osteomyelitis Market
13.1. Indonesia Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Osteomyelitis Market
14.1. South Korea Osteomyelitis Market Overview
14.2. South Korea Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Osteomyelitis Market
15.1. Western Europe Osteomyelitis Market Overview
15.2. Western Europe Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Osteomyelitis Market
16.1. UK Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Osteomyelitis Market
17.1. Germany Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Osteomyelitis Market
18.1. France Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Osteomyelitis Market
19.1. Italy Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Osteomyelitis Market
20.1. Spain Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Osteomyelitis Market
21.1. Eastern Europe Osteomyelitis Market Overview
21.2. Eastern Europe Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Osteomyelitis Market
22.1. Russia Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Osteomyelitis Market
23.1. North America Osteomyelitis Market Overview
23.2. North America Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Osteomyelitis Market
24.1. USA Osteomyelitis Market Overview
24.2. USA Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Osteomyelitis Market
25.1. Canada Osteomyelitis Market Overview
25.2. Canada Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Osteomyelitis Market
26.1. South America Osteomyelitis Market Overview
26.2. South America Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Osteomyelitis Market
27.1. Brazil Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Osteomyelitis Market
28.1. Middle East Osteomyelitis Market Overview
28.2. Middle East Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Osteomyelitis Market
29.1. Africa Osteomyelitis Market Overview
29.2. Africa Osteomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Osteomyelitis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Osteomyelitis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Osteomyelitis Market Competitive Landscape And Company Profiles
30.1. Osteomyelitis Market Competitive Landscape
30.2. Osteomyelitis Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
31. Osteomyelitis Market Other Major And Innovative Companies
31.1. Novartis AG
31.2. GSK plc
31.3. Eli Lilly and Company
31.4. Siemens Healthineers
31.5. Otsuka Pharmaceutical Co. Ltd
31.6. Fresenius Kabi AG
31.7. Sumitomo Pharma Company Limited
31.8. Hikma Pharmaceuticals PLC
31.9. Alkem Laboratories Ltd.
31.10. Torrent Pharmaceuticals Ltd.
31.11. Wockhardt Hospitals
31.12. Basilea Pharmaceutica Ltd.
31.13. Paratek Pharmaceuticals Inc.
31.14. Debiopharm International SA
31.15. Accord Healthcare Limited
32. Global Osteomyelitis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Osteomyelitis Market
34. Recent Developments In The Osteomyelitis Market
35. Osteomyelitis Market High Potential Countries, Segments and Strategies
35.1 Osteomyelitis Market In 2029 - Countries Offering Most New Opportunities
35.2 Osteomyelitis Market In 2029 - Segments Offering Most New Opportunities
35.3 Osteomyelitis Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
